Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
复制标题
纤溶酶原激活剂基因多态性与牙槽骨丢失的关联。
DOI：
10.1111/j.1600-0765.2006.00949.x
复制
发表时间：
2007
影响因子：
3.5
通讯作者：
Hardigan,P
中科院分区：
文献类型：
--
作者：
DeCarlo,AA;Grenett,H;Park,J;Balton,W;Cohen,J;Hardigan,P
Background and Objective:The plasminogen activating system is a protease/inhibitor system central to extracellular matrix remodeling with a suggested role in periodontal disease pathology. A few studies have reported polymorphisms in the genes of plasminogen activator inhibitors to be associated with periodontal disease severity. Two gene polymorphisms – aBamHI restriction fragment length polymorphism in the urokinase plasminogen activator gene (uPA) and aHindIII restriction fragment length polymorphism in the plasminogen activator inhibitor type 1 gene (PAI‐1) – have been associated with conditions having a vascular component, and our objective was to assess the association of these gene polymorphisms with alveolar bone loss in chronic periodontal disease of adults.Material and Methods:Genotype was determined by polymerase chain reaction amplification of whole blood, pertinent histories were obtained by interview, and alveolar bone loss was assessed from current radiographs.Results:In 77 elderly patients with a normal distribution of alveolar bone loss, we demonstrated a significant association between levels of alveolar bone loss and these polymorphisms in theuPAandPAI‐1genes. Controlling for the contributions of smoking or diabetes to periodontal bone loss, estimated odds ratios for predicting lower levels of alveolar bone loss, associated with a greater degree of periodontal health, were strongest when defined by the concurrent presence of a homozygous urokinase plasminogen activator genotype and the nuclease‐sensitive plasminogen activator inhibitor type 1 (HindIII) allele (odds ratio = 2.6; 95% confidence interval: 5.8–1.3).Conclusion:The urokinase plasminogen activator (BamHI) and plasminogen activator inhibitor type 1 (HindIII) genotypes may serve as useful markers for heritability of bone loss associated with periodontal disease.
